SCHEMBL4088062

SCHEMBL4088062

N#Cc1ccc(-n2c(Cl)nc3ccccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.55
RPS6KB1 P23443 2/20 0.54
GSK3B P49841 1/20 0.54
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
DRD2 P14416 1/20 0.44
TBXA2R P21731 1/20 0.44
ESR1 P03372 2/20 0.43
ESR2 Q92731 2/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
ADORA2A P29274 1/20 0.42
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP8 Q96LD8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095150 0.82 SMN1; SMN2 (0.53) LMNASMN1; SMN2ESR1ESR2MAPK1
SCHEMBL12730136 0.81 MAPK1 (0.61) SLC22A12RPS6KB1GSK3BLMNASMN1; SMN2
SCHEMBL540942 0.81 MAPK1 (0.68) SLC22A12RPS6KB1GSK3BLMNASMN1; SMN2
SCHEMBL20603917 0.79 SMN1; SMN2 (0.50) RPS6KB1GSK3BLMNASMN1; SMN2ESR1
SCHEMBL9995277 0.79 SMN1; SMN2 (0.50) SLC22A12LMNASMN1; SMN2ESR1ESR2
SCHEMBL18731715 0.79 ESR1 (0.54) SLC22A12LMNASMN1; SMN2ESR1ESR2
SCHEMBL4083024 0.79 L3MBTL1 (0.56) LMNASMN1; SMN2ESR1ESR2MAPK1
SCHEMBL18083301 0.77 RPS6KB1 (0.50) SLC22A12RPS6KB1GSK3BLMNASMN1; SMN2
SCHEMBL8027630 0.76 ESR1 (0.58) SLC22A12RPS6KB1GSK3BESR1ESR2
SCHEMBL4092820 0.76 DRD2 (0.64) LMNASMN1; SMN2DRD2TBXA2RHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
EP-1778670-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM Pharma A/S (DK) 2007-05-02 EP disclosed
WO-2006010446-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS MCHR1, MCHR2, MC1R SLC22A12 1326/4885RPS6KB1 1137/4885GSK3B 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.